A bioinformatics study demonstrated that PD-L1 mRNA expression was closely associated with poor PFS, which suggested that PD-L1 may become a promising therapeutic target for PFS of patients with ovarian cancer. This evidence concerns the gene CD274 and ovarian cancer.